Safety of Protocol Violations in Acute Stroke tPA Administration

BACKGROUND: Intravenous (IV) tissue plasminogen activator remains the only approved therapy for acute ischemic stroke (AIS) in the United States; however, less than 10% of patients receive treatment. This is partially because of the large number of contraindications, narrow treatment window, and phy...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Stroke Cerebrovasc Dis
Glavni autori: Lyerly, Michael J., Albright, Karen C., Boehme, Amelia K., Shahripour, Reza Bavarsad, Houston, James T., Rawal, Pawan V., Kapoor, Niren, Alvi, Muhammad, Sisson, April, Alexandrov, Anne W., Alexandrov, Andrei V.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4602367/
https://ncbi.nlm.nih.gov/pubmed/23954609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.07.019
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items